The collaboration highlights how enterprise AI is evolving from decision support to a core engine for IP creation and scalable product development.
NVIDIA, Moderna, and Yale review how quantum machine learning may enhance drug discovery. GPU-accelerated simulation of quantum algorithms is key to this research.
NVIDIA's NIM Agent Blueprint integrates AI models for virtual drug screening, aiming to reduce development time and costs in pharmaceuticals.
AlphaFold 3 predicts structures of DNA, RNA, ligands, and proteins. Potential to transform drug discovery. Free server available for researchers.
Mila and Sorintellis partner to use AI for optimising decision-making in clinical drug development, aiming to accelerate access to new therapies.
